10-Q: Precision BioSciences Reports Q3 Loss, Advances Gene Editing Pipeline

Precision BioSciences reported a significant net loss in Q3 2025, driven by reduced collaboration revenue, while advancing its lead gene editing programs and extending its cash runway into late 2027.

Summary

• Precision BioSciences reported a net loss of $65.9 million for the nine months ended September 30, 2025, a substantial increase from a net income of $24.9 million in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, plummeted to $0.1 million from $68.1 million in 2024, primarily due to the conclusion of the Prevail Therapeutics Agreement and decreased revenue from the Novartis Agreement.
• Operating expenses decreased to $64.7 million for the nine months ended September 30, 2025, from $69.4 million in 2024, reflecting cost reduction initiatives.
• Research and development expenses decreased by $3.9 million year-over-year, with a significant increase in PBGENE-DMD spending offset by reduced costs for PBGENE-HBV and the pausing of PBGENE-3243 development.
• Cash, cash equivalents, and restricted cash totaled $71.2 million as of September 30, 2025, down from $121.3 million in the prior year period.
• The company's cash runway is projected to be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2027.
• The collaboration and license agreement with Novartis Pharma AG was terminated, effective January 30, 2026, with all licensed rights reverting to Precision BioSciences.
• Positive clinical data was reported for the PBGENE-HBV program, which is well-tolerated and active, with dosing commenced in Cohort 3 of the ELIMINATE-B trial.
• PBGENE-DMD received Rare Pediatric Disease and Orphan Drug Designations, and preclinical data showed durable improvements in muscle function in a mouse model.
• A $8.0 million milestone payment was received from Imugene on October 31, 2025, comprising $3.0 million in cash and $5.0 million in Imugene stock, following positive efficacy data for azer-cel in lymphoma patients.

Sentiment

Score: 4

Explanation: While the company shows promising early clinical and preclinical progress in its core gene editing programs and has extended its cash runway, the significant decline in revenue and substantial increase in net loss, coupled with the termination of a major collaboration, indicate a challenging financial period. The operational positives are early-stage and carry inherent risks, outweighing the immediate financial negatives.

Positives

• PBGENE-HBV Phase 1 ELIMINATE-B trial shows the candidate is well-tolerated and active across two dose levels, with Cohort 3 dosing initiated.
• PBGENE-DMD received Rare Pediatric Disease designation in June 2025 and Orphan Drug Designation in July 2025, highlighting unmet medical need.
• Preclinical data for PBGENE-DMD demonstrated durable improvements in muscle function, increased dystrophin expression, and dystrophin-positive cells in a DMD mouse model.
• The company's cash and cash equivalents, along with expected operational receipts and ATM facility, are projected to fund operations into the second half of 2027.
• Imugene, a clinical stage partner, reported an 81% overall response rate in its Phase 1b trial for azer-cel in relapsed/refractory diffuse large B-cell lymphoma, including durable remissions.
• Imugene also reported an 83% overall response rate (50% complete responses) in CAR T-naive lymphoma patients for azer-cel.
• A $8.0 million milestone payment was received from Imugene, strengthening liquidity.
• Operating efficiencies, including employment-related and other expense reductions, were implemented to reduce annual operating expenses.

Negatives

• Net loss significantly increased to $65.9 million for the nine months ended September 30, 2025, compared to a net income of $24.9 million in the prior year.
• Revenue decreased drastically to $0.1 million for the nine months ended September 30, 2025, from $68.1 million in the same period of 2024.
• The collaboration and license agreement with Novartis Pharma AG was terminated, effective January 30, 2026, resulting in the loss of future milestone, royalty, and option payments from this partnership.
• Development of PBGENE-3243 for m.3243 associated mitochondrial disease has been paused to prioritize other lead programs.
• Cash and cash equivalents decreased from $85.9 million at December 31, 2024, to $44.9 million at September 30, 2025.
• The company continues to incur significant operating losses and does not expect to be profitable in the foreseeable future.

Risks

• Incurring significant operating losses and may not achieve or maintain profitability.
• Need for substantial additional funding; inability to raise sufficient capital could delay, reduce, or eliminate research programs, product development, and commercialization efforts.
• Limited operating history makes it difficult to evaluate current business and future prospects, increasing investment risk.
• ARCUS is a novel technology, making it difficult to predict the time, cost, and potential success of product candidate development, with limited human safety and efficacy data.
• Heavy dependence on the successful development and translation of ARCUS technology, with no assurance of successful commercialization.
• Adverse public perception of genome editing may negatively impact developmental progress or commercial success.
• Significant competition in rapidly changing industries, with competitors potentially achieving regulatory approval first or developing safer/more effective treatments.
• Future profitability depends on the ability to commercialize products globally, subject to various market risks.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The regulatory landscape for therapeutic product candidates is rigorous, complex, uncertain, and subject to change, potentially causing delays or termination of development.
• Clinical trials are difficult to design and implement, expensive, time-consuming, and involve uncertain outcomes, potentially harming the business.
• Product candidates may be complex and difficult to manufacture, leading to delays if manufacturing problems occur.
• Even with regulatory approval, products remain subject to ongoing regulatory requirements, resulting in significant additional expense.
• Approved products may fail to achieve sufficient market acceptance by physicians, patients, and healthcare payors.
• Future success depends on key executives and the ability to attract, retain, and motivate qualified personnel.
• Failure to meet Nasdaq Capital Market listing requirements could result in delisting of common stock.
• Increased costs and demands on management due to operating as a public company and no longer qualifying as an emerging growth company.
• Expenditure of limited resources on less successful or profitable programs.
• Interim, top-line, and initial data from studies or trials may change as more data become available and are subject to audit and verification.
• Product candidates may cause undesirable side effects, hindering or preventing regulatory approval or commercial potential.
• Exposure to federal, state, and foreign healthcare laws and regulations, with potential for substantial penalties for non-compliance.
• Actual or perceived failures to comply with data protection, privacy, and security laws could adversely affect business.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies could disrupt operations.
• Insurance policies are expensive and may not cover all business risks, leading to significant uninsured liabilities.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or significant costs.
• Potential misconduct or improper activity by employees, consultants, and collaborators.
• Complex tax rules and potential inability to utilize all net operating loss carryforwards.
• Reliance on third parties for research, development, and commercialization activities, with risks if collaborations are unsuccessful.
• Inability to establish collaborations on commercially reasonable terms may alter research, development, and commercialization plans.
• Reliance on third parties to conduct, supervise, and monitor clinical trials and preclinical testing, with risks of non-compliance or unsatisfactory performance.
• Reliance on third parties to supply raw materials or manufacture product supplies, with risks of shortages, quality issues, or delays.
• Inadequate protection of proprietary rights, including patents and trade secrets, could lead to competitive disadvantage.
• Third parties may assert claims of patent infringement, or the company may need to defend/enforce its patents, resulting in substantial costs or loss of productivity.
• Developments in patent law could negatively impact the patent position.
• Inability to protect the confidentiality of trade secrets and enforce intellectual property assignment agreements.
• Not seeking to protect intellectual property rights in all jurisdictions, or inability to adequately enforce them where protection is sought.
• Inability to obtain or maintain necessary rights to product components and processes for the development pipeline through acquisitions and in-licenses.
• If trademarks and trade names are not adequately protected, name recognition may not be built.
• Securities class action litigation risk.
• No current intention to pay dividends on common stock.
• Provisions in corporate documents or Delaware law might discourage, delay, or prevent a change in control or management.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Adverse or misleading opinions from securities analysts could cause stock price and trading volume to decline.
• Adverse effects from natural or man-made disasters, public health emergencies, and other catastrophic events.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials. The cash runway is projected to be sufficient into the second half of 2027, enabling potential commencement of a Phase 2 study for PBGENE-HBV and a potential pivotal study for PBGENE-DMD, pending supportive Phase 1 data readouts. The company plans to file a U.S. investigational new drug (IND) for PBGENE-DMD by the end of 2025, with Phase 1 initiation anticipated in the first half of 2026 and initial clinical data expected in the second half of 2026. Additional data readouts for PBGENE-HBV are planned in early 2026. The company will continue to explore opportunities to develop programs returned from the Novartis agreement in partnership with others.

Management Comments

• We are a gene editing company dedicated to improving life by developing in vivo therapies for genetic and infectious diseases with the application of our wholly-owned proprietary ARCUS genome editing platform.
• During the third quarter of 2025, we implemented operating efficiencies, including employment related and other expense reductions, to reduce annual operating expenses and extend our cash runway.
• Our cash runway is sufficient to enable potential commencement of a Phase 2 study for PBGENE-HBV and a potential pivotal study for PBGENE-DMD pending supportive Phase 1 data readouts.
• We have paused development of PBGENE-3243 to prioritize our two lead programs, PBGENE-HBV and PBGENE-DMD.
• The return of these programs (from Novartis) does not impact our near-term clinical priorities to finish the Phase 1 ELIMINATE-B trial for PBGENE-HBV and commence the Phase 1 trial for PBGENE-DMD, or our expected cash runway to achieve these clinical data milestones.

Industry Context

Precision BioSciences operates in the highly competitive and rapidly evolving gene editing and biopharmaceutical industries. The company's focus on in vivo gene editing therapies using its ARCUS platform positions it against other companies developing zinc finger nucleases, TALENs, and CRISPR/Cas9 technologies. The termination of the Novartis collaboration highlights the inherent risks and shifting priorities within large pharmaceutical partnerships, while the continued progress in PBGENE-HBV and PBGENE-DMD, along with positive data from the Imugene collaboration, indicates ongoing activity and potential in the gene therapy and oncology immunotherapy sectors. The receipt of Rare Pediatric Disease and Orphan Drug Designations for PBGENE-DMD underscores the industry's focus on addressing unmet needs in rare genetic diseases.

Comparison to Industry Standards

• The 81% overall response rate and 50% complete response rate reported by Imugene for azer-cel in relapsed/refractory diffuse large B-cell lymphoma and CAR T-naive lymphoma patients are competitive within the CAR T-cell therapy landscape, where other approved therapies like Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) have demonstrated high response rates in similar patient populations.
• The durable improvements in muscle function and increased dystrophin expression observed in the PBGENE-DMD mouse model are promising, aligning with the goals of other Duchenne muscular dystrophy gene therapy programs, such as those from Sarepta Therapeutics (e.g., Elevidys) and Pfizer, which aim to restore functional dystrophin protein.
• The complete clinical response in the first participant of iECURE's ECUR-506 trial for OTC deficiency at the lowest dose level (1.3x10^13 GC/kg) is a positive early indicator, comparable to initial data from other gene therapy trials for metabolic disorders, though direct comparisons require more mature data and larger patient cohorts.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal matters and claims in the ordinary course of business, but management believes there are currently no known matters that will have a material effect on the financial condition, results of operations, or cash flows.

Related Party Transactions

• Investment in Elo Life Systems, Inc. (Elo): The company holds approximately 22% of Elo's voting shares and accounts for it under the equity method. A $10.0 million promissory note receivable from Elo is outstanding, with a carrying value of $5.4 million as of September 30, 2025. The company recognized a $2.3 million gain on dilution from Elo's Series A-2 financing during the nine months ended September 30, 2025, partially offset by its proportionate share of Elo's net loss of $2.2 million.

Stakeholder Impact

• **Shareholders**: Experience significant dilution from past equity offerings and potential future capital raises. The substantial net loss and revenue decline negatively impact shareholder value, but progress in the pipeline and extended cash runway offer some long-term potential. The termination of the Novartis agreement removes a significant revenue stream but returns valuable program rights.
• **Employees**: Operating efficiencies implemented in Q3 2025 included employment-related expense reductions, which could imply workforce adjustments. Amended executive employment agreements aim to retain key management.
• **Customers/Patients**: Potential for new in vivo gene editing therapies for chronic Hepatitis B and Duchenne muscular dystrophy, addressing significant unmet medical needs. Progress in iECURE's OTC deficiency program also offers hope for patients.
• **Collaborators/Partners**: Imugene collaboration shows positive clinical results and milestone payments, indicating a successful partnership. The termination of the Novartis agreement signifies a shift in strategic focus and the return of program rights, potentially opening new collaboration opportunities for Precision BioSciences.
• **Creditors**: The company maintains a $22.5 million term loan with Banc of California, secured by a cash security account, indicating a managed debt position. The extended cash runway provides some assurance for short-to-medium term debt servicing.

Next Steps

• Continue expansion of the ELIMINATE-B clinical trial for PBGENE-HBV to higher dose levels.
• Plan additional data readouts for PBGENE-HBV in early 2026.
• Deliver a late-breaking oral presentation at the Liver Meeting 2025 on November 10, 2025, featuring new data from the first two cohorts of the ELIMINATE-B Trial.
• File a U.S. investigational new drug (IND) application for the PBGENE-DMD program by the end of 2025.
• Initiate Phase 1 clinical trials in DMD patients in the first half of 2026, pending IND clearance.
• Expect initial clinical data for PBGENE-DMD in the second half of 2026.
• Continue the OTC-HOPE study for ECUR-506 (iECURE collaboration) with data expected in the first half of 2026.
• Imugene to hold a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss potential pivotal study design options for azer-cel.
• Explore a new research collaboration with Novartis in an area of joint therapeutic interest.
• Explore opportunities to develop the returned hemoglobinopathies programs (from Novartis) in partnership with others.

Key Dates

Recommendation

Precision BioSciences is in a challenging financial position with a significant net loss and revenue decline, exacerbated by the termination of a major collaboration. However, the company has extended its cash runway into late 2027 and is making tangible progress in its lead gene editing programs (PBGENE-HBV and PBGENE-DMD), which have received important designations and shown promising early data. The return of program rights from Novartis also presents new partnering opportunities. Given the early stage of its pipeline and the high-risk, high-reward nature of gene editing, the stock is speculative. A 'hold' recommendation is appropriate as the company navigates its financial challenges while advancing its core therapeutic candidates, with significant future milestones expected to clarify its long-term potential.

Keywords

Gene Editing, ARCUS, Biotechnology, Therapeutics, Hepatitis B, Duchenne Muscular Dystrophy, Orphan Drug, Clinical Trials, SEC Filing, Financial Results, Drug Development, Biopharmaceutical, Precision BioSciences